Illumina has announced its plan to sell Grail, a cancer test developer, following a federal appeals court decision upholding the FTC's antitrust ruling against their $7.1 billion acquisition deal in 2021. This move comes after both U.S. and European Union regulators opposed the acquisition, citing concerns about diminished innovation and market competition. The sale of Grail, a company known for its early cancer detection technology, will occur through a 3rd party sale or capital market transaction.